USFDA completes inspection at Lupin’s injectable facility in Nagpur

14 Jun 2024 Evaluate

United States Food and Drug Administration (USFDA) has completed an inspection at Lupin’s Injectable facility in Nagpur, India. The inspection of the facility was carried out from June 10 to June 13, 2024, and concluded with zero 483 observations. 

Earlier, the company had entered into Business Transfer Agreement (BTA) with Lupin Life Sciences (LLSL) wholly owned subsidiary of the Company, to carve out, its trade generics business in India, as a going concern, on a slump sale basis.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2082.00 2.50 (0.12%)
30-Dec-2025 11:12 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.25
Dr. Reddys Lab 1268.25
Cipla 1485.65
Zydus Lifesciences 903.00
Lupin 2082.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×